New drug HRS-8427 tested for liver enzyme interactions in healthy volunteers
NCT ID NCT07049107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how an experimental drug called HRS-8427 affects the liver's ability to process other medications. Fourteen healthy adults took HRS-8427 along with two common drugs (bupropion and midazolam) to see if it changed their levels in the blood. The goal was to understand potential drug interactions, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-8427
- What this could lead to
- If successful, this study could help doctors understand how HRS-8427 interacts with other medications, guiding safer use in future patients.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. Results may not predict real-world effects or safety in sick people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xiangya Hospital Central South University
Changsha, Hunan, 410008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.